Table 1.

Consumer demographics (all rounds)

	Round 1 (n = 615)	Round 2 (n = 63)	Consensus building (n = 9)
Country
Australia	506 (82.3%)	61 (96.8%)	8 (88.9%)
New Zealand	42 (6.8%)	2 (3.2%)	1 (11.1%)
Missing	67 (10.9%)	-
Australian state/territory
NSW	189 (30.7%)	22 (34.9%)	2 (22.2%)
VIC	117 (19.0%)	16 (25.4%)	2 (22.2%)
QLD	86 (14.0%)	10 (15.9%)	2 (22.2%)
SA	33 (5.4%)	5 (7.9%)	2 (22.2%)
WA	34 (5.5%)	1 (1.6%)	-
TAS	19 (3.1%)	2 (3.2%)	-
ACT	27 (4.4%)	4 (6.3%)	-
NT	1 (0.2%)	1 (1.6%)	-
Missing	109 (17.7%)	-	-
Cancer type*
Bone	13 (2.1%)	-	-
Brain/central nervous system	78 (12.7%)	5 (7.9%)	-
Breast	192 (31.2%)	24 (38.1%)	1 (11.1%)
Genitourinary	1 (0.2%)	-	-
Gynaecological	23 (3.7%)	3 (4.8%)	1 (11.1%)
Haematological	34 (5.5%)	8 (12.7%)	1 (11.1%)
Head and neck	21 (3.4%)	4 (6.3%)	1 (11.1%)
Hepatobiliary	5 (0.8%)	1 (1.6%)	-
Kidney	5 (0.8%)	-	-
Lower GI	22 (3.6%)	3 (4.8%)	1 (11.1%)
Lung	41 (6.7%)	2 (3.2%)	-
Skin	68 (11.1%)	8 (12.7%)	1 (11.1%)
Thyroid	1 (0.2%)	1 (1.6%)	-
Upper GI	-	1 (1.6%)	-
Pancreatic	20 (3.3%)	1 (1.6%)	1 (11.1%)
Prostate	75 (12.2%)	8 (12.7%)	2 (22.2%)
Consumer background
Person living with cancer	440 (71.5%)	59 (93.7%)	7 (77.8%)
Spouse of person living with cancer	49 (8.0%)	3 (4.8%)	2 (22.2%)
Child of person living with cancer	10 (1.6%)	1 (1.6%)	-
Caregiver	28 (4.6%)	-	-
Other	22 (3.6%)	-	-
Missing	66 (10.7%)	-	-
Age (years), mean (SD)	54.5 (12.5) n = 542		-
Treatments received
Surgery	396 (64.4%)	48 (76.2%)	8 (88.9%)
Chemotherapy	313 (50.9%)	42 (66.7%)	8 (88.9%)
Radiation	289 (47.0%)	36 (57.1%)	5 (55.6%)
Hormone therapy	163 (26.5%)	10 (15.9%)	-
Immunotherapy	91 (14.8%)	11 (17.5%)	2 (22.2%)
Other	67 (10.9%)		2 (22.2%)

^*May not sum to 100% as patients may have had more than one diagnosis